Humoral hypercalcemia of malignancy

Summary

Humoral hypercalcemia of malignancy (MONDO:0043455) is a disease and 9 clinical trials. Top therapeutic interventions include zoledronic acid anhydrous, ibandronic acid, and parathyroid hormone. A subtype of hypercalcemia disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	humoral hypercalcemia of malignancy
Mondo ID	MONDO:0043455
MeSH	C562390
NCIT	C3496
SNOMED CT	47709007
UMLS	C0149911
MedGen	56210
GARD	0025860
Is cancer (heuristic)	no

Also known as: humoral hypercalcemia of malignancy · hypercalcemia of malignancy

Disease family

This is a subtype of hypercalcemia disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › mineral metabolism disease › calcium metabolic disease › hypercalcemia disease › humoral hypercalcemia of malignancy

Related subtypes (2): hypercalcemia, infantile, familial hypocalciuric hypercalcemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	3
PHASE1/PHASE2	2
PHASE2	1
EARLY_PHASE1	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003884	PHASE3	COMPLETED	Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
NCT00301886	PHASE3	WITHDRAWN	S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
NCT00326820	PHASE3	UNKNOWN	Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
NCT00060138	PHASE1/PHASE2	COMPLETED	Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
NCT00896454	PHASE2	COMPLETED	Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
NCT04198480	PHASE1/PHASE2	UNKNOWN	A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM
NCT01333267	PHASE1	WITHDRAWN	One Week Comparison Study of PTH and PTHrP Infusions
NCT00580788	EARLY_PHASE1	COMPLETED	One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
NCT00458796	Not specified	TERMINATED	Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ZOLEDRONIC ACID ANHYDROUS	4	8
IBANDRONIC ACID	4	4
PARATHYROID HORMONE	4	1